Akebia Therapeut Stock Price, News & Analysis

Akebia Therapeutics (AKBA) announced three upcoming poster presentations at the 62nd European Renal Association Congress 2025, taking place June 4-7 in Vienna. The presentations will focus on clinical data for vadadustat, their treatment for CKD-related anemia. Key presentations include: a cardiovascular safety analysis of vadadustat in dialysis patients presented by Dr. Glenn Chertow, a study on vadadustat's combination with ferric citrate, and real-world data comparing HIF-PH inhibitors with ESAs in non-dialysis CKD patients from a Japanese database study.

Akebia Therapeutics (NASDAQ: AKBA), a biopharmaceutical company focused on kidney disease treatments, has announced its participation in the upcoming H.C. Wainwright 3rd Annual BioConnect Investor Conference. The company's CEO John Butler and CCO Nik Grund will engage in a Fireside Chat on Tuesday, May 20, 2025, at 2:30 PM EDT at the Nasdaq Headquarters in New York City. Investors can access the presentation webcast through the "Investors" section of Akebia's website after the conference.

Akebia Therapeutics (AKBA) reported strong Q1 2025 financial results, highlighted by the successful U.S. launch of Vafseo® (vadadustat) for anemia in dialysis patients. The company generated $12.0 million in Vafseo net product revenues and total net product revenues of $55.8 million. Over 640 prescribers wrote prescriptions for Vafseo, with each averaging nearly 12 prescriptions. Auryxia® revenues reached $43.8 million. The company strengthened its financial position through a $50 million public offering, ending Q1 with $113.4 million in cash. Akebia reported a net income of $6.1 million, compared to a net loss of $18.0 million in Q1 2024. The company plans to initiate the VALOR Phase 3 trial for vadadustat in non-dialysis CKD patients in H2 2025.

Akebia Therapeutics (NASDAQ: AKBA), a biopharmaceutical company focused on kidney disease treatments, has granted stock options to eight newly-hired employees. The inducement grants total 148,000 shares of common stock with an exercise price of $2.41 per share, matching the closing price on April 30, 2025. The options feature a 4-year vesting schedule with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter. Each option has a 10-year term and is contingent on continued employment with Akebia.

Akebia Therapeutics (NASDAQ: AKBA) has announced it will release its first quarter 2025 financial results on Thursday, May 8, 2025, before market open. The company will host a conference call at 8:00 a.m. EDT on the same day to discuss the financial results and recent business highlights.

Participants are encouraged to dial in 15 minutes before the scheduled start time to ensure timely connection. A live webcast will be available through Akebia's Investors section website, with an online archive accessible afterward at ir.akebia.com.

Akebia Therapeutics (AKBA) announced that the European Medicines Agency's CHMP has adopted a positive opinion recommending approval for XOANACYL® (Ferric Citrate as Coordination Complex). The drug is intended for treating elevated serum phosphorous and iron deficiency in adult patients with chronic kidney disease (CKD).

The treatment rights in the European Economic Area and certain countries in Europe and the Middle East are licensed to Averoa, a renal-focused biopharmaceutical company. The European Commission is expected to make a final decision on XOANACYL's approval in approximately two months.

Akebia Therapeutics (Nasdaq: AKBA) has announced the granting of stock options to eight newly-hired employees as part of their inducement award program. The grants, made on March 31, 2025, total 73,325 shares of common stock with an exercise price of $1.92 per share, matching the closing price on the grant date.

The options feature a four-year vesting schedule, with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter, contingent on continued employment. Each option has a 10-year term and was granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Akebia Therapeutics (Nasdaq: AKBA) announced its upcoming participation at the National Kidney Foundation Spring Clinical Meetings 2025 (NKF SCM25) in Boston from April 10-13, 2025. The company will present two research posters:

1. A study on cardiovascular risk in patients with DD-CKD comparing Vadadustat vs Darbepoetin Alfa (Poster: G-284)

2. Research on Vadadustat's treatment of anemia comparing older vs younger patients with Dialysis-Dependent-CKD (Poster: G-285)

Dr. Wolfgang Winkelmayer will present the latter study during an oral presentation on April 10, 2025, at 4:00 pm. Attendees can visit Akebia at Booth #1121 in the Exhibit Hall.

Akebia Therapeutics (Nasdaq: AKBA) has announced the pricing of its underwritten public offering of 25,000,000 shares of common stock at $2.00 per share. The offering is expected to generate gross proceeds of $50.0 million before deducting underwriting costs and other expenses.

The company has granted underwriters a 30-day option to purchase up to 3,750,000 additional shares at the public offering price, less underwriting discounts. The offering is set to close on March 21, 2025, subject to customary conditions.

The offering is being managed by Leerink Partners and Piper Sandler & Co. as joint bookrunning managers, with BTIG, as lead manager and H.C. Wainwright & Co. as co-manager. The shares are being offered through a shelf registration statement filed with the SEC on September 3, 2024.